Skip to content
Head to head

Tarsus Pharmaceuticals vs Vertex Pharmaceuticals

Side-by-side on the measures that matter, with a plain-English read. Full detail: TARS · VRTX

Updated 7 minutes ago

1-year performance, rebased to 100

TARS -1.6%VRTX +18.7%
Vertex Pharmaceuticals edges it on the scoreable measures. Vertex Pharmaceuticals has the highest Quant Rating (68); Vertex Pharmaceuticals has done best over the past year (+22%); Vertex Pharmaceuticals earns the most per share.
TARSVRTX
Snapshot
SectorBiotechnologyBiotechnology
Last price73.01515.02
Change today-6.00%-1.08%
1-year return-5.2%+22.0%
Market cap$3.60B$130.58B
52-week range53.89 – 91.53412.27 – 568.67
Valuation
P/E (TTM)-4.6033.14
P/E percentile, own 5-yr range90th99th
P/B34.606.25
Dividend yield0.00%0.00%
Profitability & growth
EPS (TTM)-1.5915.32
Net profit (TTM)$-78.40M$3.88B
Revenue (TTM)$682.20M$12.95B
Provider revenue period date2026-09-292026-09-29
Revenue growth (YoY)+63.9%+11.8%
Gross margin93.2%85.5%
Operating margin-102.3%33.1%
Net margin-102.9%30.7%
Free cash flow (TTM)$-4.85M$3.20B
Provider cash-flow period date2026-09-292026-09-29
Ownership & sentiment
Institutional ownership108.1%96.8%
Insider activity (12mo)26 buy / 21 sell28 buy / 22 sell
Short interest (% of float)13.0%1.9%
Analyst consensus100% buy (8)95% buy / 5% hold (21)
Analyst price target$106 (+45%)$624 (+21%)
StockVane view
StockVane Quant RatingD (34)C (68)
Company
Employees3706,400
Founded20171989

▲ marks the more favourable stock(s) on measures with a clear direction (lower P/E, higher yield, higher Quant Rating, better 1-year return). Analyst consensus counts each covering institution once, at its most recent rating. Not a recommendation. Quant Rating method: Data & Methodology.